GLP-1 and Bone Density: The Other Thing the Jab Costs You

The first conversation I have with most members on a GLP-1 medication is about muscle. They have lost 12 or 15 kilograms on semaglutide or tirzepatide, they feel lighter, and the scale is the best it has read in a decade. What they have not been told is that a meaningful share of that weight was not fat. It was skeletal muscle. And underneath the muscle sits a quieter loss most clinics never measure: bone. Rapid weight loss on a GLP-1, without resistance and impact training alongside it, takes fat, muscle, and bone density together. This is the other cost of the jab, and for anyone past 40 it is the one that decides how the next three decades go.

TL;DR

Muscle goes first, and the bone follows

GLP-1 receptor agonists work by suppressing appetite. You eat less, you lose weight, and the weight comes off fast. The problem is that the body does not have a setting for losing only fat. When you run a large energy deficit without a strong resistance-training stimulus, a predictable fraction of what you lose is lean tissue. Across the GLP-1 weight-loss trials, lean mass has accounted for a substantial share of total weight lost, often in the range of a quarter to a third. I have written about this in detail in keeping your muscle while you lose fat on a GLP-1, and it is the single biggest reason these members come to us.

Muscle and bone are a structural pair. When a muscle contracts hard against load, it pulls on the bone it attaches to, and that mechanical strain is the signal that tells the skeleton to stay dense. When muscle shrinks and the load falls away, the bone has no reason to maintain itself, so it thins. This is why sarcopenia and osteoporosis travel together; the clinical name for the combination is osteosarcopenia, and it carries a worse outcome than either condition alone. The muscle loss you see in the mirror is the visible half of a process that is also hollowing out your skeleton.

What the jab costs your bones

The direct evidence is now on the table. A randomised, double-blinded, two-centre phase 2 trial published in eClinicalMedicine in 2024 gave adults at increased fracture risk once-weekly semaglutide or placebo for 52 weeks. The semaglutide group lost bone mineral density at the weight-bearing sites that matter most: the lumbar spine and the total hip, both significantly more than placebo. These are exactly the sites where osteoporotic fractures happen, and the hip is the fracture that changes the rest of someone's life.

It is worth being precise about why this happens, because it is not a mysterious drug side effect. Some bone loss is the expected consequence of fast weight loss in anyone: a lighter body loads the skeleton less, and the skeleton adjusts down. GLP-1 medications drive that weight loss harder and faster than diet alone usually can, so the bone signal is correspondingly larger. The drugs are not poisoning your bones; they are removing the load your bones were built around, and doing it quickly. That distinction points straight at the fix. If the problem is lost load, the answer is to put load back. Yet almost no one on a GLP-1 in Singapore gets a bone density scan before and after treatment. A DXA scan that reads body composition also reads bone, but most people on these drugs never get one. That silence is the gap this article is trying to close.

Why this hits hardest after 40 and around menopause

Bone density is not a fixed asset. It peaks in your late twenties, holds for a while, and then declines slowly through your forties and beyond. Layer a GLP-1's rapid weight loss on top of that natural decline and you are subtracting from an account that was already drawing down. The younger you are, the more reserve you have to absorb the hit. Past 40, the margin is thinner, and the loss is harder to rebuild.

For women, perimenopause and menopause sharpen the picture. The fall in oestrogen accelerates bone loss for several years around the menopausal transition, and this is precisely the demographic for whom GLP-1 medications are now widely prescribed. A woman in her late forties or early fifties losing weight fast on semaglutide is stacking drug-driven bone loss on top of menopausal bone loss on top of age-related bone loss. That is three subtractions at once, and it is the group I worry about most. Bone-protective training is the entire premise of our menopause and bone strength programme. The same warning holds for anyone shedding muscle without rebuilding strength; the full case for why fast muscle loss becomes the engine of later frailty is in my piece on reversing age-related muscle loss in Singapore.

Load is the signal: how resistance protects bone

The good news is that the same lever that protects muscle also protects bone, and the trial evidence is clean. The clearest demonstration comes from a 2017 study in the Journal of Gerontology that put older adults through a weight-loss programme and split them into resistance training or aerobic training. The result was decisive. Total hip and femoral neck bone density was held essentially unchanged in the resistance-training group, and it dropped in the aerobic-training group. Same weight loss, same calorie deficit, completely different bone outcome. The variable that decided it was whether the skeleton was being loaded.

A larger trial in the New England Journal of Medicine the same year reached the same conclusion from a different angle. In dieting obese older adults, the groups that did resistance training, on its own or combined with aerobic work, lost less lean mass and preserved more hip bone density than the aerobic-only group, with the combination group losing the least lean mass of all. The lesson across both trials is consistent: during weight loss, aerobic exercise is good for your heart but does almost nothing for your skeleton, while resistance training defends both the muscle and the bone you are at risk of losing.

This should reframe how anyone thinks about a GLP-1. The drug handles the appetite and the fat. It does nothing to protect the muscle and bone you are also shedding. Resistance training is the only intervention shown to stop the GLP-1 from taking your structure along with your fat.

Impact training, and the LIFTMOR evidence

Resistance training holds bone in place. The next question is whether you can do better than hold, whether you can actually rebuild bone density, and here the evidence is genuinely encouraging. The landmark trial is LIFTMOR, published in the Journal of Bone and Mineral Research in 2018. Researchers took postmenopausal women with low bone density, a group conventionally told to avoid heavy loading for fear of fracture, and put them through eight months of high-intensity resistance and impact training: heavy deadlifts, overhead press, back squats, and supervised jumping impacts, twice a week.

The results overturned the caution. Spine bone density rose by 2.9% in the training group while it fell in the control group, and femoral neck bone density and physical function both improved. Across the whole supervised programme there was only one adverse event. The conclusion was that heavy, properly coached resistance and impact training is not dangerous for fragile bones. It is one of the few things that demonstrably strengthens them. Bone, like muscle, responds to a load signal. Give it a big enough signal, under supervision, and it adapts upward.

The two words that make this safe are heavy and supervised. High-intensity loading on a low-bone-density skeleton is the wrong thing to attempt unsupervised off a video, and the right thing to do with a coach controlling the load, the technique, and the progression. That supervision is why bone-protective training for a GLP-1 member belongs in a studio, not on a living-room floor.

The Singapore context: who is on these drugs, and who is screening

GLP-1 medications are now common in Singapore. Semaglutide and tirzepatide are prescribed through GPs, endocrinology clinics, and the executive-health channels that serve the CBD professionals we train. The conversation in those clinics is overwhelmingly about how much weight comes off and how fast; the muscle and bone cost rarely makes it into the consultation. This is not a criticism of the prescribers, the drugs do what they are meant to do, but it leaves a gap that lands on exactly the demographic Singapore can least afford to lose: an ageing, increasingly long-lived population for whom a hip fracture at 70 is a catastrophe.

If you are taking a GLP-1, ask your GP or specialist clinic for a baseline DXA scan that includes bone density, not just body composition, and a repeat scan during treatment. That gives you a real measurement instead of a guess. The decision to start, continue, or adjust the medication is a medical one between you and your doctor, and nothing here is a reason to stop a drug managing your weight or metabolic health. The point is narrower: whatever the drug is doing, your training has to do the part the drug cannot.

How we handle GLP-1 members at Catalyst

Every member at Catalyst Performance, our private personal training studio at Manulife Tower above Telok Ayer MRT, starts with the 4-Pillar Healthspan Assessment, our 60-minute in-studio evaluation across body composition, cardiorespiratory fitness, stability, and strength. For a member on a GLP-1, the body composition pillar is where the story gets honest. An InBody scan separates fat mass from lean mass, so we can see whether the weight coming off is the weight you actually want to lose. If lean mass is falling, the programme changes that day.

From there the prescription writes itself, because the evidence is unambiguous. Progressive resistance training is the core, built on compound lifts loaded heavily enough to send a strong signal to both muscle and bone. Where a member's bone density and joint health allow it, we layer in controlled impact work in the spirit of the LIFTMOR protocol, coached and progressed so the load is a stimulus and never a hazard. The whole point of a supervised studio is that we can run heavy, bone-protective training safely for the exact population that most needs it and is most often told to avoid it. The full structured approach for members on these medications lives in our strength on GLP-1 programme.

The GLP-1 is doing its job on your appetite and your fat. Your job, and ours, is to make sure that when the weight comes off, your muscle and your bones stay. Lose the fat. Keep the structure. That is the entire brief.

Frequently asked questions

Q. Do GLP-1 medications actually reduce bone density?

Yes. A 2024 phase 2 trial in adults at increased fracture risk found that once-weekly semaglutide reduced bone mineral density at the lumbar spine and total hip compared to placebo over 52 weeks. Much of this reflects the bone loss that comes with any rapid weight loss, accelerated because GLP-1 medications drive weight loss faster than diet alone. The loss is largely preventable with resistance and impact training alongside the medication.

Q. Can exercise protect my bones while I lose weight on a GLP-1?

Yes, and this is well established. In weight-loss trials in older adults, resistance training preserved hip and femoral neck bone density while aerobic training alone did not. Resistance training also preserves the lean mass GLP-1 medications tend to strip. Aerobic exercise is good for your heart but does little for your skeleton during weight loss. To protect bone, the training has to load it.

Q. Is heavy lifting safe if my bone density is already low?

Under proper supervision, yes, and it may be the best thing you can do. The LIFTMOR trial put postmenopausal women with low bone density through eight months of heavy resistance and impact training and saw spine bone density rise, with only one adverse event across the programme. The conditions are heavy load and qualified coaching controlling technique and progression. Unsupervised high-intensity loading on fragile bone is not advisable; supervised loading is the intervention.

Q. Should I stop my GLP-1 because of the bone loss?

No, not on the basis of this article. Whether to start, continue, or adjust a GLP-1 is a medical decision between you and your doctor, and these drugs deliver real metabolic benefits. The message here is to pair the medication with bone-protective and muscle-protective training, and to ask your clinic for a baseline and follow-up DXA scan so the bone is actually measured rather than assumed.

Q. Why does this matter more after 40?

Bone density peaks in your late twenties and declines slowly thereafter, and around menopause the decline accelerates for several years. A GLP-1's rapid weight loss subtracts from a skeleton that is already drawing down, so the same drug-driven bone loss costs a 50-year-old more than a 30-year-old. After 40, and especially around menopause, resistance and impact training shift from helpful to essential.

Citations

Hansen MS, Wölfel EM, Jeromdesella S, et al. (2024). Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. eClinicalMedicine, 72, 102624. pmc.ncbi.nlm.nih.gov

Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. (2018). High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial. Journal of Bone and Mineral Research, 33(2), 211–220. pubmed.ncbi.nlm.nih.gov

Beavers KM, Beavers DP, Martin SB, et al. (2017). Change in Bone Mineral Density During Weight Loss with Resistance Versus Aerobic Exercise Training in Older Adults. Journal of Gerontology A: Biological Sciences and Medical Sciences, 72(11), 1582–1585. pubmed.ncbi.nlm.nih.gov

Villareal DT, Aguirre L, Gurney AB, et al. (2017). Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults. New England Journal of Medicine, 376(20), 1943–1955. pubmed.ncbi.nlm.nih.gov